# Optimizing the Treatment of Toenail Onychomycosis Using a New Transdermal Patch Combined With Terbinafine/Ketoconazole

> **NCT01615913** · PHASE1 · UNKNOWN · sponsor: **Taiwan Biotech Co., Ltd.** · enrollment: 18 (estimated)

## Conditions studied

- Onychomycosis

## Interventions

- **DRUG:** 3 mg terbinafine and 2 mg ketoconazole containing patch
- **DRUG:** 6 mg terbinafine and 2 mg ketoconazole containing patch
- **DRUG:** 8 mg terbinafine and 2 mg ketoconazole containing patch

## Key facts

- **NCT ID:** NCT01615913
- **Lead sponsor:** Taiwan Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-04
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2012-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01615913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01615913, "Optimizing the Treatment of Toenail Onychomycosis Using a New Transdermal Patch Combined With Terbinafine/Ketoconazole". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01615913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*